Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The US-China drug pipeline faces challenges as the once thriving licensing deals have dwindled in recent years, causing concern in the biopharma industry. WuXi AppTec, a critical partner to biopharma companies, is at risk if the US enforces a crackdown, leading to uncertainties and the need for backup plans.
TOO BIG TO FAIL? WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down This is 100% a topic of discussion in every biotech BOD room and almost everyone is looking for a backup or plan B https://t.co/kr7Qz4XXPR https://t.co/ZTVGvllNEX
I reviewed securities filings and interviewed companies to show the impact of a proposed US crackdown on WuXi AppTec and its affiliates. https://t.co/wX6uri0koD
"You're on a tight timeline, you’ve got cash running out, and you’ve got to get into the clinic, and all of a sudden they can't manufacture your Phase I material... that’s going to be bad" What happens if the US forces biopharma to cut ties with WuXi: https://t.co/s65gEnqNlw
